NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities and on hopes of improving trade relations between the U.S. and the European Union, while the Dow Jones posted its 7th consecutive decline. The S&P 500 Index gained 0.17 percent to close at 2,767.32, while the Nasdaq Composite jumped 0.72 percent to close at 7,781.51. The Dow Jones Industrial Average declined 0.17 percent to close at 24,657.80.

RDI Initiates Coverage on:

Clovis Oncology, Inc.
https://rdinvesting.com/news/?ticker=CLVS

Cronos Group Inc.
https://rdinvesting.com/news/?ticker=CRON

Clovis Oncology's stock jumped 5.95% Wednesday, to close the day at $48.47. The stock recorded a trading volume of 1,296,174 shares, which was below its three months average volume of 1,302,128 shares. In the last year, Clovis Oncology's shares have traded in a range of 41.31 - 99.45. The share price has gained 17.33% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $46.84 is below its 200-day moving average of $55.18. Shares of Clovis Oncology have fallen roughly 3.23 percent in the past month and are down 28.72 percent year-to-date.

Access RDI's Clovis Oncology, Inc. Research Report at:

https://rdinvesting.com/news/?ticker=CLVS

On Wednesday, shares of Cronos Group recorded a trading volume of 6,956,588 shares, which was above the three months average volume of 2,925,410 shares. The stock ended the day 5.25% higher at $7.22. The share price has fallen 30.51% from its 52 week high with a 52 week trading range of 5.12 - 10.39. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $6.43 is below its 200-day moving average of $7.07. Shares of the company are trading at a Price to Earnings ratio of 1203.33. Shares of Cronos Group have gained roughly 15.89 percent in the past month and are down 5.25 percent year-to-date.

Access RDI's Cronos Group Inc. Research Report at:

https://rdinvesting.com/news/?ticker=CRON

Our Actionable Research on Clovis Oncology, Inc. (NASDAQ: CLVS) and Cronos Group Inc. (NYSE: CRON) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email: contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com